ArticleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2012
Controlled systemic delivery by polymeric implants enhances tissue and plasma curcumin levels compared with oral administration.
Article in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Curcumin's dual effect on pyroptosis and autophagy in metabolic- associated fatty liver disease: a potential therapeutic strategy.Scientific reports · 2025Article
- Integrating Quality by Design (QbD) in Phytosomal Drug Delivery: A New Era in Precision Phytotherapy.AAPS PharmSciTech · 2025Review
- Curcumin as an antidote to atrazine on estrogen homeostasis and beyond: mechanistic insights from a targeted literature review.Frontiers in endocrinology · 2025Review
- Molecular Interactions for the Curcumin-Polymer Complex with Enhanced Anti-Inflammatory Effects.Pharmaceutics · 2019Article
- Curcumin as a potential therapeutic option for NAFLD and other metabolic diseases: need for establishing the underlying mechanism(s) of action.Hepatology international · 2019Article
- Curcumin, Cardiometabolic Health and Dementia.International journal of environmental research and public health · 2018Review
- Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - A review.Journal of traditional and complementary medicine · 2017Review
- Curcumin, inflammation, and chronic diseases: how are they linked?Molecules (Basel, Switzerland) · 2015Review
- Co-delivery of natural metabolic inhibitors in a self-microemulsifying drug delivery system for improved oral bioavailability of curcumin.Drug delivery and translational research · 2014Article
- Curcumin implants, not curcumin diet, inhibit estrogen-induced mammary carcinogenesis in ACI rats.Cancer prevention research (Philadelphia, Pa.) · 2014Article
- Sustained expression of CYPs and DNA adduct accumulation with continuous exposure to PCB126 and PCB153 through a new delivery method: Polymeric implants.Toxicology reports · 2014Article
- Bioavailability of phytochemicals and its enhancement by drug delivery systems.Cancer letters · 2013Review
- Silicon micro- and nanofabrication for medicine.Advanced healthcare materials · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Curcumin possesses potent anti-inflammatory and anti-proliferative activities but with poor biopharmaceutical attributes. To overcome these limitations, curcumin implants were developed and tissue (plasma, brain and liver) curcumin concentrations were measured in female ACI rats for 3 months. Biological efficacy of tissue levels achieved was analyzed by modulation of hepatic cytochromes. Curcumin implants exhibited diffusion-mediated biphasic release pattern with ∼2-fold higher in vivo release as compared to in vitro. Plasma curcumin concentration from implants was ∼3.3 ng/ml on day 1, which dropped to ∼0.2 ng/ml after 3 months, whereas only 0.2-0.3 ng/ml concentration was observed from 4-12 days with diet and was undetected subsequently. Almost 10-fold higher curcumin levels were observed in brain on day 1 from implants compared with diet (30.1 ± 7.3 vs 2.7 ± 0.8 ng/g) and were still significant even after 90 days (7.7 ± 3.8 vs 2.2 ± 0.8 ng/g). Although curcumin levels were similar in liver from both the routes (∼25-30 ng/g from day 1-4 and ∼10-15 ng/g at 90 days), implants were more efficacious in altering hepatic CYP1A1 levels and CYP3A4 activity at ∼28-fold lower doses at 90 days. Curcumin implants provided much higher plasma and tissue concentrations and are a viable alternative for delivery of curcumin to various organs like brain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.